Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:ABCLNASDAQ:ANABNASDAQ:IMTXNASDAQ:MOLN On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeABCLAbCellera Biologics$1.97-1.5%$2.26$1.89▼$4.34$587.90M0.462.90 million shs1.67 million shsANABAnaptysBio$20.44-1.4%$19.36$12.21▼$41.31$600.53M-0.2602,268 shs357,651 shsIMTXImmatics$5.11-1.7%$4.52$3.30▼$13.77$621.12M0.87653,124 shs375,092 shsMOLNMolecular Partners$4.05+4.2%$3.94$3.36▼$12.70$163.68M1.1521,120 shs10,089 shs20 Stocks to Sell NowToday, we are inviting you to take a free peek at our proprietary, exclusive, and up-to-the-minute list of 20 stocks that Wall Street's top analysts hate.Many of these appear to have good fundamentals and might seem like okay investments, but something is wrong. Analysts smell something seriously rotten about these companies. These are true "Strong Sell" stocks.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceABCLAbCellera Biologics0.00%-2.96%-24.23%-34.98%-48.96%ANABAnaptysBio0.00%+1.09%-0.82%+9.79%-18.37%IMTXImmatics0.00%+7.81%+9.42%+11.09%-50.58%MOLNMolecular Partners0.00%+5.57%-0.64%-15.91%+6.68%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationABCLAbCellera Biologics2.9333 of 5 stars3.42.00.00.03.93.30.6ANABAnaptysBio3.3172 of 5 stars4.43.00.00.03.21.70.6IMTXImmatics2.6872 of 5 stars3.64.00.00.03.11.70.0MOLNMolecular Partners2.1573 of 5 stars3.82.00.00.03.30.00.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceABCLAbCellera Biologics 2.75Moderate Buy$8.33323.01% UpsideANABAnaptysBio 2.70Moderate Buy$35.8875.51% UpsideIMTXImmatics 3.25Buy$17.00232.68% UpsideMOLNMolecular Partners 3.50Strong Buy$12.00196.00% UpsideCurrent Analyst Ratings BreakdownLatest MOLN, IMTX, ANAB, and ABCL Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/16/2025ABCLAbCellera BiologicsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$28.00 ➝ $10.005/6/2025ANABAnaptysBioGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetBuy ➝ Buy$52.00 ➝ $54.005/1/2025ANABAnaptysBioWedbushSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform ➝ Outperform$40.00 ➝ $40.004/16/2025ABCLAbCellera BiologicsKeyCorpSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$4.00 ➝ $5.004/1/2025IMTXImmaticsCantor FitzgeraldSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight3/26/2025ANABAnaptysBioJohnson RiceSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy3/11/2025MOLNMolecular PartnersLifesci CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageOutperform$12.003/5/2025ANABAnaptysBioJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOverweight ➝ Overweight$36.00 ➝ $42.003/4/2025ANABAnaptysBioHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral$22.00 ➝ $22.003/3/2025ANABAnaptysBioGuggenheimSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy3/3/2025ABCLAbCellera BiologicsBenchmarkSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingHold ➝ Hold(Data available from 5/25/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookABCLAbCellera Biologics$23.11M25.43N/AN/A$3.97 per share0.50ANABAnaptysBio$111.87M5.37N/AN/A$3.32 per share6.16IMTXImmatics$144.15M4.31N/AN/A$2.88 per share1.77MOLNMolecular Partners$2.23M73.33N/AN/A$5.41 per share0.75Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateABCLAbCellera Biologics-$146.40M-$0.56N/AN/AN/A-533.32%-15.73%-12.22%8/5/2025 (Estimated)ANABAnaptysBio-$163.62M-$4.85N/AN/AN/A-289.75%-287.94%-37.25%8/4/2025 (Estimated)IMTXImmatics-$104.98M-$0.17N/AN/AN/A-47.94%-15.90%-9.38%8/12/2025 (Estimated)MOLNMolecular Partners-$69.04M-$1.92N/AN/AN/A-1,043.01%-39.31%-35.46%N/ALatest MOLN, IMTX, ANAB, and ABCL EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/15/2025Q1 2025MOLNMolecular Partners-$0.3855-$0.50-$0.1145-$0.50N/AN/A5/13/2025Q1 2025IMTXImmatics-$0.39-$0.35+$0.04-$0.35$14.92 million$20.12 million5/8/2025Q1 2025ABCLAbCellera Biologics-$0.17-$0.15+$0.02-$0.15$7.12 million$4.24 million5/5/2025Q1 2025ANABAnaptysBio-$1.30-$1.28+$0.02-$1.28$15.27 million$27.77 million3/27/2025Q4 2024IMTXImmatics-$0.03$0.48+$0.51$0.48$16.16 million$15.67 million3/6/2025H2 2024MOLNMolecular Partners-$0.45-$0.34+$0.11-$0.34N/AN/A2/27/2025Q4 2024ANABAnaptysBio-$1.61-$0.72+$0.89-$0.72$10.17 million$43.11 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthABCLAbCellera BiologicsN/AN/AN/AN/AN/AANABAnaptysBioN/AN/AN/AN/AN/AIMTXImmaticsN/AN/AN/AN/AN/AMOLNMolecular PartnersN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioABCLAbCellera BiologicsN/A9.349.34ANABAnaptysBioN/A10.2310.23IMTXImmaticsN/A3.983.98MOLNMolecular PartnersN/A14.3314.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipABCLAbCellera Biologics61.42%ANABAnaptysBioN/AIMTXImmatics64.41%MOLNMolecular Partners26.55%Insider OwnershipCompanyInsider OwnershipABCLAbCellera Biologics28.90%ANABAnaptysBio33.50%IMTXImmatics3.30%MOLNMolecular Partners5.93%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableABCLAbCellera Biologics500298.42 million212.66 millionOptionableANABAnaptysBio10029.38 million20.17 millionOptionableIMTXImmatics260121.55 million115.42 millionOptionableMOLNMolecular Partners18040.38 million37.97 millionNot OptionableMOLN, IMTX, ANAB, and ABCL HeadlinesRecent News About These CompaniesQ2 Earnings Estimate for MOLN Issued By Leerink PartnrsMay 20, 2025 | americanbankingnews.comBrokers Offer Predictions for MOLN Q2 EarningsMay 20, 2025 | marketbeat.comSuvretta Capital Management LLC Has $10.55 Million Stake in Molecular Partners AG (NASDAQ:MOLN)May 19, 2025 | marketbeat.comComparing INmune Bio (NASDAQ:INMB) and Molecular Partners (NASDAQ:MOLN)May 19, 2025 | americanbankingnews.comMolecular Partners to Present at Upcoming Investor ConferencesMay 19, 2025 | globenewswire.comMolecular Partners Reports Financial Results and Highlights from Q1 2025May 16, 2025 | finance.yahoo.comBVF Inc. IL Acquires 910,747 Shares of Molecular Partners AG (NASDAQ:MOLN)May 6, 2025 | marketbeat.comMolecular Partners presents new data on Radio-DARPin, Switch-DARPin programsApril 26, 2025 | markets.businessinsider.comMolecular Partners presents new preclinical data on Radio-DARPin and Switch-DARPin programs at AACR 2025April 25, 2025 | globenewswire.comMolecular Partners (NASDAQ:MOLN) Trading 2.9% Higher - Here's What HappenedApril 25, 2025 | marketbeat.comWhy Molecular Partners AG’s (MOLN) Stock Is Up 5.04%April 17, 2025 | aaii.comMolecular Partners Announces all Board Proposals Approved at Annual General MeetingApril 16, 2025 | globenewswire.comDendi and Molecular Lab Partners Announce Strategic Partnership to Empower Labs NationwideApril 15, 2025 | tmcnet.comHedge funds owners may take dramatic actions as Molecular Partners AG's (VTX:MOLN) recent 15% drop adds to one-year lossesApril 6, 2025 | finance.yahoo.comHere's Why Molecular Partners AG Sponsored ADR (MOLN) Could be Great Choice for a Bottom FisherApril 3, 2025 | zacks.comWhy Molecular Partners AG’s (MOLN) Stock Is Up 9.28%March 27, 2025 | aaii.comMolecular Partners to hold three poster presentations at AACR 2025March 25, 2025 | globenewswire.comMolecular Partners Publishes Invitation to Annual General Meeting 2025March 25, 2025 | globenewswire.comAnalysts Have Conflicting Sentiments on These Healthcare Companies: Molecular Partners (MOLN), United Therapeutics (UTHR) and Universal Health (UHS)March 17, 2025 | markets.businessinsider.comMolecular Partners (MOLN) Initiated with a Buy at LifeSci CapitalMarch 15, 2025 | markets.businessinsider.comLifeSci Capital Initiates Coverage of Molecular Partners AG - Depositary Receipt () (MOLN) with Outperform RecommendationMarch 12, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMOLN, IMTX, ANAB, and ABCL Company DescriptionsAbCellera Biologics NASDAQ:ABCL$1.97 -0.03 (-1.50%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$2.00 +0.03 (+1.27%) As of 05/23/2025 07:51 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AbCellera Biologics Inc. builds an engine for antibody drug discovery and development. Its engine discovers antibodies from natural immune responses, which are pre-enriched for antibodies. The company's preclinical products are ABCL635 for metabolic and endocrine conditions; and ABCL575 for atopic dermatitis. It has a research collaboration and license agreement with Eli Lilly and Company; a research collaboration with Confo Therapeutics for the discovery of therapeutic antibody candidates targeting two undisclosed GPCR targets; and strategic collaboration with Biogen Inc. to discover therapeutic antibodies for neurological conditions, as well as collaboration with Viking Global Investors and ArrowMark Partners. The company was incorporated in 2012 and is headquartered in Vancouver, Canada.AnaptysBio NASDAQ:ANAB$20.44 -0.30 (-1.45%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$20.40 -0.04 (-0.20%) As of 05/23/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AnaptysBio, Inc., a clinical-stage biotechnology company, focuses in delivering immunology therapeutics. Its products include Rosnilimab, an IgG1 antibody that targets PD-1+ T cells, resulting in their agonism or depletion, broadly impacting pathogenic drivers of autoimmune and inflammatory diseases; and ANB032, a non-depleting antibody that binds to the BTLA checkpoint receptor and inhibits activated T cell proliferation; ANB033, a novel anti-CD122 antagonist antibody that targets the shared common beta subunit of the receptors for IL-15 and IL-2; ANB101, a BDCA2 modulator antibody that specifically targets plasmacytoid dendritic cells (pDCs); and Imsidolimab, an antibody that inhibits the interleukin-36 receptor, which is in the Phase 3 development for the treatment of generalized pustular psoriasis. The company also focuses on developing various antibody programs that are advanced to preclinical and clinical milestones under its collaborations. It has a collaboration and license agreement with GlaxoSmithKline, Inc. The company was formerly known as Anaptys Biosciences, Inc. and changed its name to AnaptysBio, Inc. in July 2006. AnaptysBio, Inc. was incorporated in 2005 and is based in San Diego, California.Immatics NASDAQ:IMTX$5.11 -0.09 (-1.73%) Closing price 05/23/2025 04:00 PM EasternExtended Trading$5.12 +0.01 (+0.20%) As of 05/23/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics. Its products pipeline includes IMA203 that targets solid tumors, which is in Phase 1b clinical trial; IMA203CD8, a cell therapy product that is in Phase 1b clinical trial; IMA204 that targets tumor stroma, which is in preclinical stage; and IMA30x, an allogenic cellular therapy product candidate, which is in preclinical stage. The company also develops TCR Bispecifics products, including IMA401 and IMA402, which is in Phase 1a clinical trial. The company has a strategic collaboration agreement with MD Anderson Cancer Center to develop multiple T cell and TCR-based adoptive cellular therapies; Celgene Corporation to develop novel adoptive cell therapies targeting multiple cancers; and Genmab A/S to develop T cell engaging bispecific immunotherapies targeting multiple cancer indications. Immatics N.V. is headquartered in Tübingen, Germany.Molecular Partners NASDAQ:MOLN$4.05 +0.16 (+4.22%) Closing price 05/23/2025 03:56 PM EasternExtended Trading$4.06 +0.00 (+0.02%) As of 05/23/2025 04:04 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Molecular Partners AG, a clinical-stage biotechnology company, develops designed ankyrin repeat proteins therapeutics for the treatment of oncology and virology diseases in Switzerland. The company develops MP0317, a CD40 agonist designed to activate immune cells within the tumor microenvironment by anchoring to fibroblast activation protein that is in Phase I clinical trial; and MP0533, a novel tetra-specific T cell-engaging DARPin for acute myeloid leukemia. It also develops Switch-DARPin platform, a multispecific cKIT x CD16a x CD47 Switch-DARPin program for targeted and conditional immune cell activation; and Radio-DARPin Therapy (RDT) platform, a delivery system for effective and selective delivery of radioactive payloads to solid tumors. It has license and research collaboration agreements with Novartis Pharma AG to develop DARPin-conjugated radioligand therapies; and collaboration agreement with Orano Med SAS to develop novel Radio-DARPin therapeutics. Molecular Partners AG was incorporated in 2004 and is headquartered in Schlieren, Switzerland. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/19 - 05/23 Trade Desk Silences Critics; Recovery Looks Poised to Continue Booz Allen Hamilton Earnings: 3 Bullish Signals for BAH Stock Turbulence for Joby Shares: What's Behind the Recent Dip? Pfizer's 7.5% Dividend: Income Haven or House of Cards? TJX Stock Price Stumble Is Your Chance to Pick Up a Bargain These ETFs Provide Easy Exposure to Growing International Markets Advance Auto Parts Jumps on Surprise Earnings Beat Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
